Thrombolytic Therapy in the Elderly: Pharmacoeconomic Considerations

Drugs and Aging

Volumn 8, Issue 4, 1996, Pages 237-244

  Ramanathan, Krishnan ^a   Ellis, Christopher J ^a   White, Harvey D ^a  

^a GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANISTREPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW;

AGED; COST-BENEFIT ANALYSIS; HUMANS; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATORS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0029962283     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608040-00002     Document Type: Article

References (52)

1. Stason WB, Sanders CA, Smith HC. Cardiovascular care of the elderly: economic consideration. J Am Coll Cardiol 1987; 10: 18A-21A
2. Roig E, Castaner A, Simmons B, et al. In-hospital mortality rates from acute myocardial infarction by race in US hospitals: findings from the National Hospital Discharge Survey. Circulation 1987; 76: 280-8
3. Goldberg RJ, Gore JM, Gurwitz JH. The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester heart attack study. Am Heart J 1989; 117: 543-9
4. Norris RM, Brandt PWT, Caughey DE, et al. A new coronary prognostic index. Lancet 1969; 1: 274-8
5. Hillis LD, Forman S, Braunwald E, et al. Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1990; 16: 313-5
6. Muggioni AP, Franzosi JG, Santoro E, et al. Analysis of the risk of stroke in 20 891 patients with acute myocardial infarction following thrombolytic and antithrombotic treatment. N Engl J Med 1992; 327: 1-6
7. Stevenson R, Ranjadayalan K, Wilkinson P, et al. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. BMJ 1993; 307: 349-53
8. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results of an international trial of 41,021 patients. Circulation 1995; 91: 1659-68
9. Himbert D, Steg PG, Juliard JM, et al. Eligibility for reperfusion therapy and outcome in elderly patients with acute myocardial infarction. Eur Heart J 1994; 15: 483-8
10. Weaver WD, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991; 18: 657-62
11. Williamson BD, Muller DW, Topol EJ. Should older patients with acute myocardial infarction receive thrombolytic therapy? Drugs Aging 1992; 2 (6): 461-8
12. Fibrinolytic Therapy Trialists' Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22
13. Rogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Circulation 1994; 90: 2103-14
14. Gunnar RM, Passamani ER, Bourdillon PD, et al. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular procedures (Subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). J Am Coll Cardiol 1990; 16: 249-92
15. Gurwitz JH, Goldberg RJ, Gore JM. Coronary thrombolysis for the elderly? JAMA 1991; 265: 1720-3
16. Rawles JM, Hailes NE. Patient and general practitioner delay in acute myocardial infarction. BMJ 1988; 296: 882-4
17. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402
18. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; II: 349-60
19. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; I: 545-9
20. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet 1988; II: 525-30
21. ISAM (Intravenous Streptokinase in Acute Myocardial Infarction) Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314: 1465-71
22. Rossi P, Bolognese L, on behalf of Urochinasi per via Sistemica nell'Infarto Miocardico (USIM) Collaborative Group. Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Am J Cardiol 1991; 68: 585-92
23. ISIS-3 (Third International Study of Infarct Survival) collaborative group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin along among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70
24. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 1993; 342: 767-72
25. LATE Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-66
26. Mark DB. Economic analysis methods and endpoints. In: Califf RM, Mark DB, Wagner GS, editors. Acute coronary care in the thrombolytic era. 2nd ed. St Louis: Mosby-Year Book, 1995: 167-82
27. Vermeer F, Simoons ML, de Zwaan C, et al. Cost benefit analysis of early thrombolytic treatment with intracoronary streptokinase: twelve month follow up report of the randomised multicentre trial conducted by the Interuniversity Cardiology Institute of the Netherlands. Br Heart J 1988; 59: 527-34
28. Simoons ML, Vos J, Martens LL. Cost-utility analysis of thrombolytic therapy. Eur Heart J 1991; 12: 694-9
29. Krumholz HM, Pasternak RC, Weinstein MC, et al. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. N Engl J Med 1992; 327: 7-13
30. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24
31. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71
32. The International Study Group. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990, 336: 71-5
33. Laffel GL, Fineberg HV, Braunwald E. A cost-effectiveness model for coronary thrombolysis/reperfusion therapy. J Am Coll Cardiol 1987; 10: Suppl. B: 79B-90B
34. Steinberg EP, Topol EJ, Sakin JW, et al. Cost and procedure implications of thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1988; 12: Suppl. A: 58A-68A
35. Agnelli G, Buchanan MR, Fernandez F, et al. The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. Thromb Res 1985; 40: 769-77
36. Eisert WG, Muller TH. Bolus treatment of t-PA expedites rate of lysis in vivo without increasing risk of bleeding [abstract]. Blood 1987; 70 Suppl. 1: 370a
37. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329 (10): 673-82
38. Katz A, Cohn G, Mashal A, et al. Case report. Thrombolytic therapy for acute myocardial infarction in a 110 year old man. Am J Cardiol 1993; 71: 1122-3
39. The GUSTO Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329 (22): 1615-22
40. Simes JR, Topol EJ, Holmes DR, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion: importance of early and complete infarct artery reperfusion. Circulation 1995; 91: 1923-8
41. White HD. Selecting a thrombolytic agent. Cardiol Clin 1995; 13 (3): 347-54
42. White HD, Granger C, Gore J, et al. Older age is associated with a large increase in mortality and total stroke, but not non-fatal disabling stroke: results of the GUSTO trial [abstract]. Circulation 1994; 90: 1-563
43. Kalish SC, Gurwitz JH, Krumholz HM, et al. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995; 10: 321-30
44. Lee TH. Cost effectiveness of tissue plasminogen activator [editorial]. N Engl J Med 1995; 332: 1443-4
45. Mark DB. Medical economics and health policy issues for interventional cardiology. In: Topol EJ, editor. Textbook of interventional cardiology. 2nd ed. Philadelphia: WB Saunders, 1994: 1323-53
46. Pryor DB, Horrell Jr FE, Rankin JS, et al. Trends in the presentation, management and survival of patients with coronary artery disease: the Duke database for cardiovascular disease. In: Higgins MW, Luepker RV, editors. Trends in coronary heart disease mortality: the influence of medical care. New York: Oxford University Press, 1988: 76-87
47. Cerqueira MD, Maynard C, Ritchie JD, et al. Long term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction trials. J Am Coll Cardiol 1992; 20: 1452-9
48. Simoons ML, Vos J, Tijssen JGP, et al. Long-term benefits of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989; 14: 1609-15
49. Baigent C, Collins R. ISIS-2: 4 year mortality follow up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction [abstract]. Circulation 1993; 88 Suppl. II: 1-290
50. Taylor GJ, Moses HW, Katholi RE, et al. Six year survival after coronary thrombolysis and early revascularization for acute myocardial infarction. Am J Cardiol 1992; 70: 26-30
51. Rose EA. Is the use of t-PA as compared with streptokinase cost effective [letter]? N Engl J Med 1995; 333: 1009
52. Armentono R, Favaloro RG. Is the use of t-PA as compared with streptokinase cost effective [letter]? N Engl J Med 1995; 333: 1009-10